BackKiniksa Pharmaceuticals International Plc. Overview
Kiniksa Pharmaceuticals International Plc. - Ordinary Shares - Class A

Kiniksa Pharmaceuticals International Plc. Target Price

Analysts' average 12-month price target for Kiniksa Pharmaceuticals International Plc. is $85.

Get informed when a big investor buys or sells

+ Follow

Share Price

$77.91

Average Target Price

$84.678.7% upside

6 analysts in the last 4 months

High: $99 | Low: $72

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-30Goldman SachsPaul Choi$9015.5% upsideOpen
2026-07-29Wedbush$9927.1% upsideOpen
2026-07-29Canaccord GenuityEdward Nash$9825.8% upsideOpen
2026-07-23Goldman SachsPaul Choi$753.7% downsideOpen
2026-07-13Wells Fargo$745% downsideOpen
2026-06-29Wedbush$727.6% downsideOpen
2026-04-29Wedbush$5924.3% downsideOpen
2026-04-28JefferiesRoger Song$718.9% downsideOpen
2026-04-16Wedbush$5825.6% downsideOpen
2026-02-19Canaccord Genuity$6220.4% downsideOpen
2026-01-13WedbushDavid Nierengarten$5035.8% downsideOpen
2025-10-29Goldman Sachs$5529.4% downsideOpen
2025-10-13Wedbush$4443.5% downsideOpen
2025-07-29Jefferies$5430.7% downsideOpen
2024-10-29Evercore ISILiisa Bayko$3555.1% downsideOpen
2024-09-13JefferiesRoger Song$4048.7% downsideOpen
2024-05-03Wells FargoEva Fortea Verdejo$3456.4% downsideOpen

Kiniksa Pharmaceuticals International Plc. (KNSA) FAQ

Kiniksa Pharmaceuticals International Plc. posts a target price of $85. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $85 for KNSA means covering analysts, on average, see the stock 8.7% upside of $77.91 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for KNSA's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Kiniksa Pharmaceuticals International Plc.'s other metric pages and overview cover the third.

Judging Kiniksa Pharmaceuticals International Plc. against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $85 here, then scan peer and history charts to see if the gap is persistent.